SARS-COV-2 vaccine responses in renal patient populations

Rona M. Smith¹,²,³*, Daniel J. Cooper¹,², Rainer Doffinger², Hannah Stacey², Abdulrahman Al-Mohammad², Ian Goodfellow⁴, Stephen Baker¹, Sara Lear², Myra Hosmilo⁶, Nicholas Pritchard², Nicholas Torpey², David Jayne¹,², Vivien Yiu⁵, Anil Chalisey², Jacinta Lee¹, Enric Vilnar⁶, Chee Kay Cheung⁷,⁸ and Rachel B. Jones¹,²

Abstract

Background: Dialysis patients and immunosuppressed renal patients are at increased risk of COVID-19 and were excluded from vaccine trials. We conducted a prospective multicentre study to assess SARS-CoV-2 vaccine antibody responses in dialysis patients and renal transplant recipients, and patients receiving immunosuppression for autoimmune disease.

Methods: Patients were recruited from three UK centres (ethics:20/EM/0180) and compared to healthy controls (ethics:17/EE/0025). SARS-CoV-2 IgG antibodies to spike protein were measured using a multiplex Luminex assay, after first and second doses of Pfizer BioNTech BNT162b2(Pfizer) or Oxford-AstraZeneca ChAdOx1nCoV-19(AZ) vaccine.

Results: Six hundred ninety-two patients were included (260 dialysis, 209 transplant, 223 autoimmune disease (prior rituximab 128(57%)) and 144 healthy controls. 299(43%) patients received Pfizer vaccine and 379(55%) received AZ. Following two vaccine doses, positive responses occurred in 96% dialysis, 52% transplant, 70% autoimmune patients and 100% of healthy controls. In dialysis patients, higher antibody responses were observed with the Pfizer vaccination. Predictors of poor antibody response were triple immunosuppression (adjusted odds ratio [aOR]0.016;95%CI0.002–0.13; p < 0.001) and mycophenolate mofetil (MMF) (aOR0.2;95%CI 0.1–0.42; p < 0.001) in transplant patients; rituximab within 12 months in autoimmune patients (aOR0.29;95%CI 0.008–0.096; p < 0.001) and patients receiving immunosuppression with eGFR 15–29 ml/min (aOR0.031;95%CI 0.11–0.84; p = 0.021). Lower antibody responses were associated with a higher chance of a breakthrough infection.

Conclusions: Amongst dialysis, kidney transplant and autoimmune populations SARS-CoV-2 vaccine antibody responses are reduced compared to healthy controls. A reduced response to vaccination was associated with rituximab, MMF, triple immunosuppression CKD stage 4. Vaccine responses increased after the second dose, suggesting low-responder groups should be prioritised for repeated vaccination. Greater antibody responses were observed with the mRNA Pfizer vaccine compared to adenovirus AZ vaccine in dialysis patients suggesting that Pfizer SARS-CoV-2 vaccine should be the preferred vaccine choice in this sub-group.

Keywords: Vaccine, SARS-CoV-2, Immunosuppression, Rituximab, Mycophenolate, Transplant, Dialysis, Autoimmune, Antibody

Introduction

The renal patient population is diverse, including individuals requiring renal replacement therapy in the form of dialysis, and those receiving immunosuppression as a result of renal transplantation or for autoimmune

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
diseases, such as vasculitis, systemic lupus erythematosus (SLE) or primary glomerulonephritis (GN). SARS-CoV-2 infection is associated with high morbidity and mortality in these complex patients [1]. The vulnerability of these individuals led to public health advice for them to adopt extended protective self-isolation measures early in the pandemic, and they were prioritised for vaccination against SARS-CoV-2. In the UK, most are being offered third doses of SARS CoV-2 vaccines in the autumn of 2021.

Vaccine trials have been successful in the general population and have shown that some vaccines are up to 95% effective at preventing symptomatic infection [2, 3]. However, patients with end stage kidney disease and those receiving immunosuppressive medications were largely excluded from the initial SARS-CoV-2 vaccine trials. Historically, vaccination against other infections results in suboptimal responses in these patients [4–6]. Vaccines against SARS-CoV-2 approved for use in the UK include the mRNA vaccines Pfizer BioNTech BNT162b2 (Pfizer) and Moderna mRNA-1273; and the Adenovirus vector vaccines Oxford-AstraZeneca ChAdOx1 nCoV-19 (AZ) and Janssen Ad26.COV2-S.

Several groups have now reported on the immunogenicity of SARS-CoV-2 vaccines in immunocompromised patients. The serologic response to mRNA vaccines in patients receiving dialysis has been encouraging. One study, which included 1256 dialysis patients, reported seroconversion rates of 85–95% after the second dose; comparable to healthy controls [7]. However, antibody titres are lower when compared with healthy controls despite high seroconversion rates [8]. Most studies have assessed the effectiveness of mRNA vaccines and few report the neutralising capacity of antibodies, but a UK multi-centre cohort study of 178 haemodialysis patients revealed that infection-naive patients had a markedly reduced neutralising antibody response to the AZ vaccine compared to the Pfizer vaccine, although the difference was reduced in individuals that experienced an infection prior to or vaccination [9]. Risk factors for reduced immunogenic response in dialysis patients included older age, comorbidities and dialysis vintage.

In contrast, antibody production after mRNA vaccination is poor in individuals with a renal transplant with less than 60% generating protective level antibodies after the second dose [9, 10]. Comparison of the Pfizer and AZ vaccines in kidney transplant patients reported enhanced humoral responses with the Pfizer vaccine, however T-cell responses to both vaccines were attenuated when compared to healthy controls [11]. A reduced antibody response was associated with older age, more recent transplantation and anti-metabolite drugs, such as mycophenolate mofetil (MMF).

Less data is available on patients with autoimmune disease, and disease heterogeneity makes interpretation more challenging. The OCTAVE trial is assessing SARS-CoV-2 vaccine responses (to both Pfizer and AZ vaccines) in patients with chronic immune-mediated diseases on immunosuppression including individuals with inflammatory arthritis, ANCA-associated vasculitis, inflammatory bowel disease, hepatic disease and malignancy [12]. Preliminary data indicates that although 89% of patients seroconverted 4 weeks after the second vaccine dose, 40% generated lower levels of antibodies compared to healthy subjects. 72% of patients with ANCA-associated vasculitis (N=30), who had all received rituximab, did not generate detectable antibodies, although T cell responses in all sub-groups were similar to those in healthy individuals. In addition to the poor antibody response following rituximab (particularly if rituximab has been administered within 6 months prior to the vaccine), glucocorticoids and methotrexate have also been associated with reduced antibody levels [13–16].

We conducted a prospective cohort study to assess differences and predictors of SARS-CoV-2 antibody responses following vaccination in three immunocompromised renal populations; dialysis, renal transplant and patients receiving immunosuppression for multisystem autoimmune disease. The use of the same assay across groups allowed direct comparison across renal patient populations as well as with healthy controls. Additionally, the majority of patients recruited to this study received the AZ vaccine, therefore addressing the relative paucity of data on responses to adenovirus vector vaccines in the existing literature. Our cohort includes over 100 individuals who have received the B-cell depletion therapy with rituximab, a population of particular interest.

Methods
This prospective observational cohort study included patients recruited from the Departments of Nephrology, at Cambridge University Hospitals NHS Foundation Trust, East and North Hertfordshire NHS Trust and University Hospitals of Leicester NHS Trust in the UK (ethics reference: 20/EM/0180). Healthy controls were recruited at Cambridge University Hospitals NHS Foundation Trust (ethics reference: 17/EE/0025). Patients receiving dialysis or immunosuppression following either renal transplantation or for autoimmune renal disease were eligible. Patients receiving IVlg or plasma exchange were excluded to avoid potential confounders of vaccine response. Blood sampling was performed approximately three monthly for up to 18 months. Flexibility in the timing of blood samples was permitted to align sampling with 4–6 weeks post COVID vaccine administration during the study, as well as (wherever possible) aligning with
routine clinical tests and access to blood testing facilities. Clinical data were collected from electronic medical records and patient interviews and included baseline demographics, changes to immunosuppressive medication over time and data on episodes of SARS-CoV-2 infection. SARS-CoV-2 IgG antibodies to spike protein (wild type Wuhan variant) were measured using a UKAS accredited multiplex Luminex assay following the first and second doses of either Pfizer BioNTech BNT162b2 (Pfizer) or Oxford-AstraZeneca ChAdOx1 nCoV-19 (AZ) vaccine. Spike antibody MFI titres greater than 1896 were considered positive, with a sensitivity of 92% and specificity of 99% as determined by ROC analysis, nucleocapsid antibody titres of > 6104 were considered positive for previous natural infection [17, 18]. Statistical analyses were performed using Stata version 14. Between group differences in proportional response to vaccine were compared using chi-squared test. Median spike antibody titres were compared using Wilcoxon rank-sum test. Multivariate logistic regression modelling was used to evaluate the odds of vaccine response.

Results

Patient characteristics and baseline demographics

Results on 692 patients are reported (260 dialysis; 209 transplant and 223 with autoimmune disease) between 21 January 2021 and 6th August 2021. Samples after the first vaccine dose were available for 234 (90%) dialysis, 180 (86%) transplant and 152 (73%) autoimmune disease patients and after the second dose for 236 (91%), 185 (89%) and 201 (90%) patients respectively. Median age was 62 (range 19–95) years. Diabetes was the cause of end stage renal failure in 59 (23%) of patients on haemodialysis. For those individuals not on dialysis, median eGFR was 62 ml/min (IQR: 42–90). Prior PCR confirmed SARS-CoV-2 infection was documented in 39 individuals (6%) (Table 1). A nucleocapsid titre suggestive of prior SARS-CoV-2 natural infection was seen in 50 individuals (7%). Healthy controls (n = 144) with s-antibody titres measured at 28 days post-second dose of vaccine were used for comparison. Median age was 40 (range 20–73) years; 32 (27%) were male, and all healthy controls had received two doses of the Pfizer vaccine (Pfizer BioNTech BNT162b2).

The median time from renal transplantation was 1264 (IQR 355–3788) days. 29 (14%) patients had received a combined kidney and pancreas transplant. 68 (33%) patients were on 3 agents for immunosuppression – most commonly low dose prednisolone, a calcineurin inhibitor (tacrolimus) and anti-metabolite (mycophenolic acid [MMF] or azathioprine). 130 (62%) were receiving MMF (Table 2). In the autoimmune population, disease subgroups were classified as: ANCA-associated vasculitis (AAV) 133 (60%); systemic lupus erythematosus (SLE) 27 (12%); large vessel vasculitis 11 (5%) and other 52 (24%). One hundred twenty-eight patients had received

### Table 1

Demographics according to patient group; dialysis, renal transplant or autoimmune disease

|                       | Dialysis N = 260 | Transplant N = 209 | Autoimmune N = 223 |
|-----------------------|------------------|------------------|-------------------|
| Age (years) (median (range)) | 71 (20–95)       | 57 (23–78)       | 59 (19–88)        |
| Sex (male) (Number (%))           | 149 (63)         | 108 (58)         | 90 (47)           |
| Vaccine type (Number (%))          |                  |                  |                   |
| ‑ Pfizer                        | 159 (61)         | 140 (67)         | 80 (36)           |
| ‑ AstraZeneca                   | 92 (36)          | 69 (33)          | 138 (62)          |
| ‑ Unknown                       | 9 (3)            | 0 (0)            | 5 (2)             |
| Days between first and second vaccine doses (median (IQR)) |                  |                  |                   |
| ‑ Pfizer                        | 77 (21–150)      | 77 (21–100)      | 76 (22–91)        |
| ‑ AstraZeneca                   | 77 (25–144)      | 77 (35–102)      | 77 (27–135)       |
| PCR proven prior Covid-19 infection (Number(%)) | 20 (8)           | 14 (7)           | 5 (2)             |
| Samples after 1st vaccine dose (Number(%)) | 234 (90)        | 180 (86)         | 152 (73)          |
| ‑ Days after vaccination (median (IQR)) | 30 (18–88)      | 28 (14–75)       | 38 (21–118)       |
| Samples after 2nd vaccine dose (Number(%)) | 236 (91)         | 185 (89)         | 201 (90)          |
| ‑ Days after vaccination (median (IQR)) | 30 (12–119)     | 30 (11–94)       | 33 (19–75)        |
| S antibody titre after first vaccine dose (IU) | 7450 (2940–19,457) | 556 (189–3936)  | 1388 (157–11,714) |
| ‑ Number(% positive)             | 189–234 (81)    | 61/180 (34)      | 69/152 (45)       |
| S antibody titre after second vaccine dose (IU) | 30,807 (26593–31,914) | 4285 (295–26,230) | 18,673 (1127–30,470) |
| ‑ Number(% positive)             | 227/236 (96)    | 104/185 (56)     | 140/201 (70)      |

Dialysis patients were recruited from Cambridge (n = 217) and East and North Hertfordshire (n = 43). Data are reported at the time of most recent sampling. Antibody MFI titres greater than 1896 are considered positive.
rituximab, a median of 162 (IQR 110–275) days prior to vaccination (Table 3).

**Antibody titres by group and vaccine choice**

The Pfizer vaccine was administered in 299 patients (43.2%), AZ in 379 (54.8%). Vaccine type was unknown in 14 (2%). Antibody levels were measured at a median 30 days (IQR: 28–37) after first vaccine dose and 30 days (IQR 30–34) after second vaccine dose. The median intervals between the first and second doses of the Pfizer and AZ vaccines were 77 days (IQR 71–78) and 77 days (IQR 70–80) respectively. In the healthy control cohort, all s-antibody titres were measured at 28 days post-second vaccine dose.

Median spike protein antibody titres were higher at 28 days-post second vaccine dose after Pfizer vaccine (30,178 [IQR 7800 – 31,813]) compared to the AZ vaccine (14,539 [IQR 794–29,888]) across the whole cohort (not including healthy controls; p < 0.001). After second dose of vaccine, median spike protein antibody titre was 30,807 (IQR 26,593 – 31,914) in dialysis, 18,673 (I127 – 30,470) in autoimmune disease and 4285 (295–26,230) in transplant patients (p < 0.001 for all between-group comparisons; Fig. 1A). A higher proportion of dialysis patients had a positive antibody response (227/236; 96%) than those with autoimmune disease (140/209; 52%; p < 0.001) or a transplant (109/209; 52%; p < 0.001). Within the dialysis cohort: median s-antibody titres in HD were higher with Pfizer 31,135 (IQR 29,544 – 32,025) compared to 28,619 (IQR 11,086 – 31,263) with AZ (p < 0.001). No differences in titre by vaccine type were observed in either the autoimmune (p = 0.09) or transplant cohorts (p = 0.86) (Fig. 1B).

**Antibody response by MMF and prednisolone status**

Within the transplant cohort, median s-antibody titres were lower in those taking MMF (1145 [IQR 1084–1207]) compared to those not taking MMF (1251 [IQR 1098–1300]) (p = 0.01). Median s-antibody titres were lower in those taking prednisolone (1145 [IQR 1084–1207]) compared to those not taking prednisolone (1300 [IQR 1150–1450]) (p = 0.002).
199–12,258]) compared to those not taking MMF (15,091 [2197 – 30,059]; \( p < 0.001 \); Fig. 2A). Median s-antibody titre at 28 days-post second vaccine dose was lower in those taking prednisolone in any cohort (9593 [IQR 438–29,496]) compared to those not taking prednisolone (29,182 [IQR 6438–31,662]; \( p < 0.001 \)). A higher proportion of those not taking prednisolone had a successful vaccine response (327/391; 84%) than those who were (144/231; 62%; \( p < 0.001 \)).

Effects of rituximab timing on vaccine response in autoimmune patients
Median s-antibody titres correlated strongly with time from most recent Rituximab treatment (Spearman’s correlation coefficient 0.46; \( p < 0.001 \)), with increasing time from dose correlating with higher s-antibody titres. A lower median s-antibody was seen in those who had received Rituximab in the 6 months preceding a second vaccine dose (690 [IQR 175–12,767]) compared to receiving a second vaccine dose greater than 6 months since most recent Rituximab treatment (27,975 (1534 – 31,199); \( p < 0.001 \); Fig. 2B). No difference was seen in median s-antibody titres between those who received a second vaccine dose < 1 month since previous rituximab treatment compared to 1–3 months since rituximab treatment, and similarly, no difference was seen in those receiving a second dose of vaccine between 1 and 3 months since Rituximab treatment compared to 3–6 months since Rituximab treatment. A lower median s-antibody titre was seen in those having a second dose of vaccine between 3 and 6 months from most recent Rituximab treatment (1341 [IQR 207–12,158]) compared to those receiving a second dose of vaccine 6–12 months since previous Rituximab treatment (10,075 [IQR 553–30,226]; \( p = 0.032 \)). Similarly, those receiving a second dose of vaccine between 6 and 12 months since most recent Rituximab treatment had a lower median s-antibody titre than if rituximab had been given more than 12 months prior to second dose of vaccine (30,648 [IQR 27975–32,114]; \( p = 0.0035 \)).

Multivariate regression of factors associated with odds of vaccine response
In a multivariate logistic regression model, lower odds of vaccine response were associated with triple immunosuppression (adjusted odds ratio [aOR] 0.016; 95% CI 0.002–0.13; \( p < 0.001 \)), MMF in transplant patients (aOR 0.2; 95% CI 0.1–0.42; \( p < 0.001 \)), prior rituximab within
the last 12 months for autoimmune disease (aOR 0.29; 95% CI 0.008–0.096; \( p < 0.001 \)) and GFR less than 29 ml/min in patients receiving immunosuppression (aOR 0.031; 95% CI 0.11–0.84; \( p = 0.021 \)) (Fig. 3). Concurrent prednisolone in any group was associated with a lower odds of a successful vaccine response (aOR 0.55; 95% CI 0.34–0.90; \( p = 0.017 \)). Prior PCR confirmed Covid-19 infection was the only factor associated with a higher odds ratio of vaccine response (aOR 5.11, 95% CI 1.29–20.35; \( p = 0.021 \)).
Breakthrough infections
PCR confirmed infections at greater than 28 days post-vaccination were reported in 56 patients to date; 23 dialysis patients (9%), 17 autoimmune disease patients (8%) and 16 transplant patients (8%). Of these breakthrough infections, 31 were male and 25 were female. Post-vaccination median spike antibody titres were lower in those who had breakthrough infections compared to those who did not (11,511 [IQR 1215 – 29,506] vs 30,036 [IQR 6110 – 32,459]; \( p = 0.0001 \)). A ROC analysis identified a cut-off for spike antibody titre of 7629 for identifying the group who had breakthrough infection, with an AUC of 0.44, however sensitivity and specificity were low at 61 and 27% respectively. There was a trend towards lower age in those with breakthrough infections (mean 57 years [SD 15.7] in those with breakthrough infection vs 61 years [SD 18] in those without; \( p = 0.08 \)). There was no difference in vaccine type in those with breakthrough infections (29 had AZ, 27 had Pfizer; \( p = 0.73 \)).

Discussion
Nephrologists are involved in the care of a heterogeneous group of complex patients. These individuals often have comorbidities other than their kidney diagnosis, and are vulnerable to severe Covid-19 infection. This multi-centre study provides real world comparable data on vaccine efficacy in three immunocompromised renal populations compared to healthy controls. More than 50% of patients in this cohort had received the AZ SARS-CoV-2 vaccine, enabling comparison between mRNA and adenoviral vaccines to be made.

In all patient groups, antibody titre and the proportion of patients with positive antibody responses incremented following a second dose of vaccine. Although positive antibody responses were observed in 97% of dialysis patients, only 52% of renal transplant recipients and 70% of autoimmune patients had positive titres after the second vaccine dose. Median titres in transplant recipients were lower than both autoimmune and dialysis patients, and median titres in autoimmune patients lower than dialysis patients. In dialysis patients, antibody responses were higher with the mRNA Pfizer vaccine compared to AZ adenovirus vaccine and lower overall compared to healthy controls. A lower spike antibody titre following 2 doses of vaccine was associated with a higher likelihood of breakthrough infection.

Key predictors of poor vaccine response were receiving triple immunosuppression or concurrent MMF in transplant recipients, immunosuppression use in patients with CKD stage 4/5 and B cell depletion (prior rituximab therapy) in autoimmune patients. There was a clear positive correlation between time since last rituximab and antibody titre with 94% of patients achieving a positive antibody response when a second vaccine dose was administered more than 12 months after last rituximab dose. These data suggest that repeating vaccination more than 12 months after last Rituximab dose may have a beneficial effect on antibody response to vaccination. For stable patients receiving ongoing repeat rituximab dosing, where clinically appropriate, postponing routine rituximab dosing to optimise vaccine timing and response may be considered, provide close monitoring of patients is in place to avoid relapse [19]. The majority of patients in our autoimmune disease population received rituximab for ANCA-associated vasculitis (AAV), where for remission maintenance fixed interval 6 monthly rituximab dosing is frequently used [20]. Alternative dosing strategies with longer dosing intervals and dosing according to peripheral blood CD19 B cell return and PR3/MPO-ANCA rise may be reasonable, temporarily, in stable vasculitis patients with low relapse risk and experienced clinician oversight, to help optimise vaccine responses [19].

Strengths of this study are the inclusion of three renal patient populations and healthy controls, with evaluation of antibody response on the same diagnostic platform enabling results to be directly compared. In addition, the large number of rituximab treated patients is of particular interest and has enabled the time dependent effect of rituximab to be demonstrated on vaccine response. The frequency of prior COVID 19 infection was low in our population which allowed assessment of vaccine response without the confounding effect of prior infection in the majority. Limitations of the data presented include lack of data on T cell response and neutralising capacity of the antibodies. This is particularly important for those individuals with sub-optimal antibody titres, in whom a weak positive result may offer a false reassurance/overestimate of protection and a borderline negative antibody result may falsely imply no protection at all. Work is ongoing to assess the durability of response and the impact of third dose vaccinations in these immunocompromised renal patient populations.

Conclusion
These data provide insight into patient subgroups at greatest risk for suboptimal SARS-CoV-2 vaccine response. Although, it is not possible to make individual patient recommendations based on this data, patients on triple immunosuppression or MMF following renal transplantation, autoimmune patients receiving rituximab, and patients with CKD stage 4/5 receiving immunosuppression are at greatest risk for poor vaccine response. These groups should be prioritised for repeated vaccination. At the time of vaccination, temporary reduction of immunosuppression could be considered, but a careful balance between transplant rejection risk/autoimmune
disease flare and achieving adequate vaccine response is required, and decisions should be made on an individual basis only by an experienced nephrologist. Reducing prednisolone dose alone, where possible, may have a beneficial effect on response to vaccination. For autoimmune patients, the positive correlation between vaccine response and time since rituximab suggests that delaying routine remission maintenance dosing could be considered; provided relapse risk is deemed to be low and adequate relapse monitoring is in place. Although third and fourth SARS-CoV-2 vaccine doses may allow a further increment in the proportion of patients with detectable antibodies, it remains vital that antibody durability and function is assessed in immunosuppressed patients to identify the most vulnerable sub-populations in whom additional COVID-19 prevention strategies will be of greatest benefit.

Acknowledgements
All the patients that participated in this study and all the nephrologists and research staff (especially Lisa Willcocks, Viola Ricco, Donner Goymer, Luca D’Agnano, Cécilia Matarar, Ann-Marie O’Sullivan, Claire Freeman, Rita Ng, Diankantha Kumararatne, Hugh Cahill) in the Department of Renal Medicine, Cambridge University Hospitals who contributed to this study and the Cambridge Biomedical Research Centre who provided infrastructure to support this study.

Authors’ contributions
RS, DC, RD and RJ are responsible for conception and design of the study; RS, RJ, AAM, HS, NP, NT, AC, VY, DJ, EV, J. and KCC collected the data; IG, SB, SL, DC and MH contributed to the design and conduct of the healthy control cohort; DC, RS, RD and RJ analysed and interpreted the data; RS, DC and RJ drafted the article; RS, RJ, DC, RD, AAM, HS, EV and KCC critically revised the article. All authors approve the final version to be published.

Funding
This study was funded by Addenbrooke’s Charitable Trust and Vasculitis UK and supported by Cambridge Biomedical Research Centre. IG was supported by grants from the Wellcome Trust (Ref. 207498/Z/17/Z) and UKRI (MR/W005611/1).

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available as the study is ongoing with further time points for data collection, and final analysis of the dataset is currently incomplete, but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved:
1. The prospective observational cohort study (ethics reference: 20/EM/0180) by East Midlands - Leicester Central Research Ethics Committee.
2. Healthy controls (ethics reference: 17/EE/0025) by East of England - Cambridge Central Research Ethics Committee.

Consent for publication
Not applicable.

Competing interests
RM Smith has received research grants from Uxion Therapeutics, GlaxoSmithKline, LifeArc, Kidney Research UK and Addenbrooke’s Charitable Trust. IG has received charitable research grants from the Wellcome Trust and UKRI. SL has received a charitable research grant from Addenbrookes Charitable Trust. DRW Jayne’s disclosures of commercial conflicts for companies are: Astra-Zeneca, Aurinia, BMS, Boehringer-Ingelheim, GSK, Janssen, Novartis, Roche/Gentech, Takeda & Vifor. CK Cheung has received a research grant from GlaxoSmithKline and advisory board fees from Vifor Pharma. RB Jones has received research grants from GlaxoSmithKline and Roche and advisory board fees from Vifor Pharma and GlaxoSmithKline. Rest of the authors have no Conflict of interest to declare.

The results presented in this paper have not been published previously in whole or part, except in abstract format.

Author details
1 Department of Medicine, University of Cambridge, Cambridge, UK. 2 Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 3 Department of Renal Medicine, Addenbrooke’s Hospital, Hills Road, Box 118, Cambridge CB2 0QQ, UK. 4 Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK. 5 West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK. 6 East and North Hertfordshire NHS Trust, Stevenage, UK. 7 Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. 8 University Hospitals of Leicester NHS Trust, Leicester, UK.

Received: 24 December 2021 Accepted: 11 April 2022
Published online: 31 May 2022

References
1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
2. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577 Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.
3. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 384(5):403–416. doi: https://doi.org/10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.
4. Krueger KM, Ison MG, Gheesin C. Practical guide to vaccination in all stages of CKD, including patients treated by Dialysis or kidney transplant. Am J Kidney Dis. 2020;75:417–25. https://doi.org/10.1053/j.ajkd.2019.06.014.
5. Bingham CO 3rd, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64–74. https://doi.org/10.1002/art.25034.
6. van Assen S, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62:75–81. https://doi.org/10.1002/art.25033.
7. Stumpf J, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021;100178. https://doi.org/10.1016/j.lanepe.2021.100178 Epub ahead of print. PMID: 34318288; PMCID: PMC8292827.
8. Carr EJ, et al. Review of early immune response to SARS-CoV-2 vaccination among patients with CKD. Kidney Int Rep. 2021;6(9):2292–304.
9. Carr EJ, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021. https://doi.org/10.1016/S1470-2959(21)00353-6
doi: https://doi.org/10.1016/S1470-2959(21)00353-6. Epub ahead of print. Erratum in: Lancet. 2021 Aug 17; PMID: 34391504; PMCID: PMC8360704.
10. Boyarsky BJ, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–6. https://doi.org/10.1001/jama.2021.7489 PMID: 33950155; PMCID: PMC7787219.
11. Prendecchi M, et al. Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. MedRiv. https://doi.org/10.1016/j.medri.2021.07.09.21260192.
12. Keams, P et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE Trial.
13. Spiera R, Jinich S, Jannat-Khadi D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis.
Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.